Watson Launches Generic Zyban
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson launched its "authorized" generic of GlaxoSmithKline's Zyban (bupropion 150 mg) on May 28
You may also be interested in...
Zyban Generics Enter Market; Impax/Teva Launch After Andrx Surrenders Exclusivity
Andrx will share in the profits of Impax/Teva’s bupropion 150 mg for smoking cessation for six months. Relinquishment of first-to-file rights mirrors Andrx’ earlier decision to give up exclusivity on Wellbutrin SR.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.